- Stocks
- Pharma & Healthcare
- Neuland Laboratories
Neuland Laboratories share price
NSE: NEULANDLABPharma & HealthcareDrug Manufacturers - Specialty & Generic
Neuland Laboratories at a glance
Neuland Laboratories (NSE: NEULANDLAB) closed at ₹18,745.00 on 21 Oct 2026, down 2.57% on the day. With a market capitalisation of ₹24,050 Cr, it ranks 316th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 65.9× trailing earnings, against a return on equity of 19.4% in FY26. Over the past year the share price has risen 15.6%. Its 52-week range is ₹11,500.00 (23 Mar 2026) to ₹24,225.00 (9 Sep 2026); the last close is 22.6% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹642 Cr (+119.2% year on year) and net profit ₹148 Cr (+962.4%), on a consolidated basis. Promoters held 32.62% of the company as of 30 Jun 2026; 2.29% of promoter shares were pledged.
Key numbers
- Market cap
- ₹24,050 CrRank 316 on NSE
- P/E (trailing)
- 65.9×
- Price to book
- 8.27×FY26
- EPS (TTM)
- ₹387.97to Q1 FY27
- ROE
- 19.4%FY26
- ROCE
- 23.1%FY26
- Debt to equity
- 0.1FY26
- Net profit margin
- 18.0%FY26
- Book value / share
- ₹1,452.37FY26
- Dividend payout
- 4.2%FY26
- 52-week high
- ₹24,225.009 Sep 2026
- 52-week low
- ₹11,500.0023 Mar 2026
- 1-year return
- +15.6%
- RSI (14-day)
- 20.8
Returns to 21 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −2.57% | −8.0% | −17.4% | −0.7% | +15.6% |
Neuland Laboratories quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹311 Cr | ₹398 Cr | ₹328 Cr | ₹293 Cr | ₹514 Cr | ₹440 Cr | ₹776 Cr | ₹642 Cr |
| Revenue YoY | −25.6% | +1.3% | −14.7% | −33.4% | +65.4% | +10.5% | +136.4% | +119.2% |
| Net profit | ₹33 Cr | ₹102 Cr | ₹28 Cr | ₹14 Cr | ₹97 Cr | ₹41 Cr | ₹213 Cr | ₹148 Cr |
| Net profit YoY | −63.2% | +24.8% | −58.8% | −85.8% | +194.9% | −60.1% | +664.7% | +962.4% |
| Net margin | 10.6% | 25.5% | 8.5% | 4.7% | 18.8% | 9.2% | 27.4% | 23.0% |
| EPS | ₹25.60 | ₹79.18 | ₹21.67 | ₹10.83 | ₹75.49 | ₹31.62 | ₹165.76 | ₹115.10 |
Neuland Laboratories financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹937 Cr | ₹951 Cr | ₹1,191 Cr | ₹1,559 Cr | ₹1,477 Cr | — |
| Operating profit | ₹105 Cr | ₹82 Cr | ₹216 Cr | ₹401 Cr | ₹270 Cr | — |
| Net profit | ₹81 Cr | ₹64 Cr | ₹164 Cr | ₹300 Cr | ₹260 Cr | — |
| EPS (₹) | ₹63.00 | ₹50.00 | ₹127.00 | ₹234.00 | ₹203.00 | — |
| Cash from operations | ₹189 Cr | ₹59 Cr | ₹237 Cr | ₹261 Cr | ₹317 Cr | — |
| Total debt | ₹88 Cr | ₹104 Cr | ₹74 Cr | ₹45 Cr | ₹91 Cr | ₹161 Cr |
| Shareholders' equity | ₹786 Cr | ₹841 Cr | ₹994 Cr | ₹1,283 Cr | ₹1,525 Cr | ₹1,874 Cr |
Neuland Laboratories shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 32.68% | 32.68% | 32.64% | 32.63% | 32.63% | 32.62% |
| Foreign institutions | 22.11% | 21.69% | 20.60% | 20.90% | 20.46% | 21.08% |
| Domestic institutions | 10.97% | 11.57% | 13.54% | 14.71% | 15.84% | 16.51% |
| Non-institutions | 33.84% | 33.67% | 32.81% | 31.76% | 31.07% | 29.79% |
| Promoter shares pledged | — | — | — | — | 2.29% | 2.29% |
Neuland Laboratories vs peers
The listed Pharma & Healthcare companies nearest to Neuland Laboratories by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| KIMSKrishna Institute of Medical Sciences | ₹672.75 | −0.47% | −5.5% | ₹28,256 Cr | 112.1 | 18.0% |
| PPLPHARMAPiramal Pharma | ₹198.24 | +2.19% | +0.4% | ₹26,393 Cr | 25 | −4.0% |
| NEULANDLABNeuland Laboratories | ₹18,745.00 | −2.57% | +15.6% | ₹24,050 Cr | 65.9 | 19.4% |
| RUBICONRubicon Research | ₹1,433.20 | −3.30% | — | ₹23,703 Cr | 93.9 | 19.1% |
| PGHHProcter Gamble | ₹7,006.50 | −1.46% | −50.3% | ₹22,744 Cr | 26.5 | 62.3% |
| PIRPHYTOPiramal Phytoca | — | — | — | ₹21,083 Cr | — | — |
| SAGILITYSAGILITY | ₹43.69 | −0.59% | −5.5% | ₹20,453 Cr | 22.1 | 9.6% |
Ask anything about Neuland Laboratories
Pivot answers on the live chart with evidence you can check, and tests strategies against NEULANDLAB's own history. Try: “Why has NEULANDLAB moved over the last three months?” · “Backtest a 50-day moving-average crossover on NEULANDLAB over five years” · “Compare NEULANDLAB with KIMS on margins and valuation”
Frequently asked questions about Neuland Laboratories
What is the share price of Neuland Laboratories today?
Neuland Laboratories (NSE: NEULANDLAB) last closed at ₹18,745.00 on 21 Oct 2026. Its 52-week high is ₹24,225.00 and its 52-week low is ₹11,500.00.
What is the market cap of Neuland Laboratories?
Neuland Laboratories' market capitalisation is ₹24,050 Cr (₹24,050 Cr) at the 21 Oct 2026 close, ranking 316th among the NSE companies Pivot tracks.
What is the P/E ratio of Neuland Laboratories?
Neuland Laboratories trades at a trailing P/E of 65.9. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 26.5.
What is the ROE and ROCE of Neuland Laboratories?
Return on equity was 19.4% in FY26 and return on capital employed was 23.1% in FY26 (consolidated figures).
Is Neuland Laboratories a debt-free company?
No. Neuland Laboratories' debt-to-equity ratio was 0.1 in FY26, with total debt of ₹161 Cr.
What were Neuland Laboratories' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Neuland Laboratories reported revenue of ₹642 Cr, +119.2% year on year, and net profit of ₹148 Cr, +962.4% year on year.
How has Neuland Laboratories stock performed over the last year?
Neuland Laboratories' share price has risen 15.6% over the past year, −0.7% over three months and −17.4% over one month, to the 21 Oct 2026 close.
What is the shareholding pattern of Neuland Laboratories?
As of 30 Jun 2026: promoters 32.62%, foreign institutions 21.08%, domestic institutions 16.51%, non-institutions 29.79%. 2.29% of promoter shares were pledged.
Who are Neuland Laboratories' competitors?
The listed Pharma & Healthcare companies closest to Neuland Laboratories by market cap are Krishna Institute of Medical Sciences, Piramal Pharma, Rubicon Research, Procter Gamble, Piramal Phytoca and SAGILITY.
Is Neuland Laboratories a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Neuland Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NEULANDLAB against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026 (returns and ratios at the 21 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with N · all NSE stocks · this page as text